GRI Bio Inc News - GRI

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI...

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a...

GRI Bio Regains Compliance with Nasdaq

LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant...

GRI Bio to Present at the 8th Annual IPF Summit

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Announces Closing of $4.0 Million Public Offering

LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Company is strategically building a global patent estate in key territories for a growing pipeline targeting...

GRI Bio Announces Pricing of $4 Million Public Offering

LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA...

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI...

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

Data recently presented at the 2024 American Thoracic Society International Conference and the 14th...

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date...

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of...

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE...

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GRI Bio Inc (GRI)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GRI News

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Announces Pricing of $4 Million Public Offering

GRI Bio Announces Reverse Stock Split

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GRI Bio Inc (GRI) News

GRI Bio Inc (GRI)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GRI News

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Announces Pricing of $4 Million Public Offering

GRI Bio Announces Reverse Stock Split

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Discussion

Your Recent History